{
  "symbol": "UNH",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2125,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.183
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 30,717 $ 25,312 Short-term investments 3,574 3,801 Accounts receivable, net 26,936 22,365 Other current receivables, net 26,022 26,089 Prepaid expenses and other current assets 9,036 8,212 Total current assets 96,285 85,779 Long-term investments 51,863 52,354 Property, equipment and capitalized software, net 10,734 10,553 Goodwill 107,566 106,734 Other intangible assets, net 22,947 23,268 Other assets 20,395 19,590 Total assets $ 309,790 $ 298,278 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 37,136 $ 34,224 Accounts payable and accrued liabilities 33,566 34,337 Short-term borrowings and current maturities of long-term debt 9,986 4,545 Unearned revenues 3,296 3,317 Other current liabilities 29,487 27,346 Total current liabilities 113,471 103,769 Long-term debt, less current maturities 71,285 72,359 Deferred income taxes 3,902 3,620 Other liabilities 15,963 15,939 Total liabilities 204,621 195,687 Commitments and contingencies (Note 6) Redeemable noncontrolling interests 4,358 4,323 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 910 and 915 issued and outstanding 9 9 Retained earnings 97,934 96,036 Accumulated other comprehensive loss ( 2,905 ) ( 3,387 ) Nonredeemable noncontrolling interests 5,773 5,610 Total equity 100,811 98,268 Total liabilities, redeemable noncontrolling interests and equity $ 309,790 $ 298,278 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended March 31, (in millions, except per share data) 2025 2024 Revenues: Premiums $ 86,534 $ 77,988 Products 13,036 11,909 Services 8,972 8,888 Investment and other income 1,033 1,011 Total revenues 109,575 99,796 Operating costs: Medical costs 73,411 65,735 Operating costs 13,594 14,077 Cost of products sold 12,390 11,056 Depreciation and amortization 1,061 997 Total operating costs 100,456 91,865 Earnings from operations 9,119 7,931 Interest expense ( 998 ) ( 844 ) Loss on sale of subsidiary and subsidiaries held for sale ( 15 ) ( 7,086 ) Earnings before income taxes 8,106 1 Provision for income taxes ( 1,632 ) ( 1,222 ) Net earnings (loss) 6,474 ( 1,221 ) Earnings attributable to noncontrolling interests ( 182 ) ( 188 ) Net earnings (loss) attributable to UnitedHealth Group common shareholders $ 6,292 $ ( 1,409 ) Earnings (loss) per share attributable to UnitedHealth Group common shareholders: Basic $ 6.90 $ ( 1.53 ) Diluted $ 6.85 $ ( 1.53 ) Basic weighted-average number of common shares outstanding 912 922 Dilutive effect of common share equivalents 6 \u2014 Diluted weighted-average number of common shares outstanding 918 922 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 6 15 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended March 31, (in millions) 2025 2024 Net earnings (loss) $ 6,474 $ ( 1,221 ) Other comprehensive income: Gross unrealized gains (losses) on investment securities during the period 521 ( 290 ) Income tax effect ( 119 ) 68 Total unrealized gains (losses), net of tax 402 ( 222 ) Gross reclassification adjustment for net realized gains included in net earnings ( 10 ) ( 32 ) Income tax effect 2 7 Total reclassification adjustment, net of tax ( 8 ) ( 25 ) Foreign currency translation gains (losses) 88 ( 293 ) Reclassification adjustment for translation losses included in net earnings (loss) \u2014 4,128 Total foreign currency translation gains 88 3,835 Other comprehensive income 482 3,588 Comprehensive income 6,956 2,367 Comprehensive income attributable to noncontrolling interests ( 182 ) ( 188 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 6,774 $ 2,179 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended March 31, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2025 915 $ 9 $ \u2014 $ 96,036 $ ( 2,226 ) $ ( 1,161 ) $ 5,610 $ 98,268 Net earnings 6,292 148 6,440 Other comprehensive income 394 88 482 Issuances of common stock, and related tax effects 1 \u2014 183 183 Share-based compensation 362 362 Common share repurchases ( 6 ) \u2014 ( 540 ) ( 2,482 ) ( 3,022 ) Cash dividends paid on common shares ($ 2.10 per share) ( 1,912 ) ( 1,912 ) Redeemable noncontrolling interests fair value and other adjustments ( 5 ) ( 5 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 194 194 Distribution to nonredeemable noncontrolling interests ( 179 ) ( 179 ) Balance at March 31, 2025 910 9 \u2014 97,934 ( 1,832 ) ( 1,073 ) 5,773 100,811 Balance at January 1, 2024 924 $ 9 $ \u2014 $ 95,774 $ ( 1,971 ) $ ( 5,056 ) $ 5,665 $ 94,421 Net (loss) earnings ( 1,409 ) 149 ( 1,260 ) Other comprehensive (loss) income ( 247 ) 3,835 3,588 Issuances of common stock, and related tax effects 2 \u2014 242 242 Share-based compensation 352 352 Common share repurchases ( 6 ) \u2014 ( 574 ) ( 2,518 ) ( 3,092 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,729 ) ( 1,729 ) Redeemable noncontrolling interests fair value and other adjustments ( 20 ) ( 20 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 19 19 Distribution to nonredeemable noncontrolling interests ( 151 ) ( 151 ) Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, (in millions) 2025 2024 Operating activities Net earnings (loss) $ 6,474 $ ( 1,221 ) Noncash items: Depreciation and amortization 1,061 997 Deferred income taxes 64 ( 27 ) Share-based compensation 375 372 Loss on sale of subsidiary and subsidiaries held for sale 15 7,086 Other, net 97 179 Net change in other operating items, net of effects from acquisitions and dispositions: Accounts receivable ( 4,462 ) ( 6,162 ) Other assets ( 544 ) ( 1,927 ) Medical costs payable 2,993 2,069 Accounts payable and other liabilities ( 607 ) ( 231 ) Unearned revenues ( 10 ) 9 Cash flows from operating activities 5,456 1,144 Investing activities Purchases of investments ( 4,135 ) ( 4,798 ) Sales of investments 3,185 2,976 Maturities of investments 2,167 2,314 Cash paid for acquisitions and other transactions, net of cash assumed ( 702 ) ( 3,006 ) Purchases of property, equipment and capitalized software ( 898 ) ( 743 ) Loans to care providers - cyberattack \u2014 ( 2,164 ) Repayments of care provider loans - cyberattack 891 \u2014 Other, net ( 582 ) ( 919 ) Cash flows used for investing activities ( 74 ) ( 6,340 ) Financing activities Common share repurchases ( 3,000 ) ( 3,072 ) Cash dividends paid ( 1,912 ) ( 1,729 ) Proceeds from common stock issuances 360 486 Repayments of long-term debt \u2014 ( 750 ) Proceeds from short-term borrowings, net 3,911 6,189 Proceeds from \ne segment.",
      "score": 0.9978
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 777 $ 645 $ (4,142) $ (8,978) 1 389 322 (2,117) (4,896) (1) (389) (305) 2,169 5,927 (2) (777) (610) 4,350 13,169 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 777 $ 645 $ (4,142) $ (8,978) 1 389 322 (2,117) (4,896) (1) (389) (305) 2,169 5,927 (2) (777) (610) 4,350 13,169 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships."
  ],
  "curated_text": "Symbol: UNH. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 30,717 $ 25,312 Short-term investments 3,574 3,801 Accounts receivable, net 26,936 22,365 Other current receivables, net 26,022 26,089 Prepaid expenses and other current assets 9,036 8,212 Total current assets 96,285 85,779 Long-term investments 51,863 52,354 Property, equipment and capitalized software, net 10,734 10,553 Goodwill 107,566 106,734 Other intangible assets, net 22,947 23,268 Other assets 20,395 19,590 Total assets $ 309,790 $ 298,278 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 37,136 $ 34,224 Accounts payable and accrued liabilities 33,566 34,337 Short-term borrowings and current maturities of long-term debt 9,986 4,545 Unearned revenues 3,296 3,317 Other current liabilities 29,487 27,346 Total current liabilities 113,471 103,769 Long-term debt, less current maturities 71,285 72,359 Deferred income taxes 3,902 3,620 Other liabilities 15,963 15,939 Total liabilities 204,621 195,687 Commitments and contingencies (Note 6) Redeemable noncontrolling interests 4,358 4,323 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 910 and 915 issued and outstanding 9 9 Retained earnings 97,934 96,036 Accumulated other comprehensive loss ( 2,905 ) ( 3,387 ) Nonredeemable noncontrolling interests 5,773 5,610 Total equity 100,811 98,268 Total liabilities, redeemable noncontrolling interests and equity $ 309,790 $ 298,278 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended March 31, (in millions, except per share data) 2025 2024 Revenues: Premiums $ 86,534 $ 77,988 Products 13,036 11,909 Services 8,972 8,888 Investment and other income 1,033 1,011 Total revenues 109,575 99,796 Operating costs: Medical costs 73,411 65,735 Operating costs 13,594 14,077 Cost of products sold 12,390 11,056 Depreciation and amortization 1,061 997 Total operating costs 100,456 91,865 Earnings from operations 9,119 7,931 Interest expense ( 998 ) ( 844 ) Loss on sale of subsidiary and subsidiaries held for sale ( 15 ) ( 7,086 ) Earnings before income taxes 8,106 1 Provision for income taxes ( 1,632 ) ( 1,222 ) Net earnings (loss) 6,474 ( 1,221 ) Earnings attributable to noncontrolling interests ( 182 ) ( 188 ) Net earnings (loss) attributable to UnitedHealth Group common shareholders $ 6,292 $ ( 1,409 ) Earnings (loss) per share attributable to UnitedHealth Group common shareholders: Basic $ 6.90 $ ( 1.53 ) Diluted $ 6.85 $ ( 1.53 ) Basic weighted-average number of common shares outstanding 912 922 Dilutive effect of common share equivalents 6 \u2014 Diluted weighted-average number of common shares outstanding 918 922 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 6 15 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended March 31, (in millions) 2025 2024 Net earnings (loss) $ 6,474 $ ( 1,221 ) Other comprehensive income: Gross unrealized gains (losses) on investment securities during the period 521 ( 290 ) Income tax effect ( 119 ) 68 Total unrealized gains (losses), net of tax 402 ( 222 ) Gross reclassification adjustment for net realized gains included in net earnings ( 10 ) ( 32 ) Income tax effect 2 7 Total reclassification adjustment, net of tax ( 8 ) ( 25 ) Foreign currency translation gains (losses) 88 ( 293 ) Reclassification adjustment for translation losses included in net earnings (loss) \u2014 4,128 Total foreign currency translation gains 88 3,835 Other comprehensive income 482 3,588 Comprehensive income 6,956 2,367 Comprehensive income attributable to noncontrolling interests ( 182 ) ( 188 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 6,774 $ 2,179 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended March 31, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2025 915 $ 9 $ \u2014 $ 96,036 $ ( 2,226 ) $ ( 1,161 ) $ 5,610 $ 98,268 Net earnings 6,292 148 6,440 Other comprehensive income 394 88 482 Issuances of common stock, and related tax effects 1 \u2014 183 183 Share-based compensation 362 362 Common share repurchases ( 6 ) \u2014 ( 540 ) ( 2,482 ) ( 3,022 ) Cash dividends paid on common shares ($ 2.10 per share) ( 1,912 ) ( 1,912 ) Redeemable noncontrolling interests fair value and other adjustments ( 5 ) ( 5 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 194 194 Distribution to nonredeemable noncontrolling interests ( 179 ) ( 179 ) Balance at March 31, 2025 910 9 \u2014 97,934 ( 1,832 ) ( 1,073 ) 5,773 100,811 Balance at January 1, 2024 924 $ 9 $ \u2014 $ 95,774 $ ( 1,971 ) $ ( 5,056 ) $ 5,665 $ 94,421 Net (loss) earnings ( 1,409 ) 149 ( 1,260 ) Other comprehensive (loss) income ( 247 ) 3,835 3,588 Issuances of common stock, and related tax effects 2 \u2014 242 242 Share-based compensation 352 352 Common share repurchases ( 6 ) \u2014 ( 574 ) ( 2,518 ) ( 3,092 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,729 ) ( 1,729 ) Redeemable noncontrolling interests fair value and other adjustments ( 20 ) ( 20 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 19 19 Distribution to nonredeemable noncontrolling interests ( 151 ) ( 151 ) Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, (in millions) 2025 2024 Operating activities Net earnings (loss) $ 6,474 $ ( 1,221 ) Noncash items: Depreciation and amortization 1,061 997 Deferred income taxes 64 ( 27 ) Share-based compensation 375 372 Loss on sale of subsidiary and subsidiaries held for sale 15 7,086 Other, net 97 179 Net change in other operating items, net of effects from acquisitions and dispositions: Accounts receivable ( 4,462 ) ( 6,162 ) Other assets ( 544 ) ( 1,927 ) Medical costs payable 2,993 2,069 Accounts payable and other liabilities ( 607 ) ( 231 ) Unearned revenues ( 10 ) 9 Cash flows from operating activities 5,456 1,144 Investing activities Purchases of investments ( 4,135 ) ( 4,798 ) Sales of investments 3,185 2,976 Maturities of investments 2,167 2,314 Cash paid for acquisitions and other transactions, net of cash assumed ( 702 ) ( 3,006 ) Purchases of property, equipment and capitalized software ( 898 ) ( 743 ) Loans to care providers - cyberattack \u2014 ( 2,164 ) Repayments of care provider loans - cyberattack 891 \u2014 Other, net ( 582 ) ( 919 ) Cash flows used for investing activities ( 74 ) ( 6,340 ) Financing activities Common share repurchases ( 3,000 ) ( 3,072 ) Cash dividends paid ( 1,912 ) ( 1,729 ) Proceeds from common stock issuances 360 486 Repayments of long-term debt \u2014 ( 750 ) Proceeds from short-term borrowings, net 3,911 6,189 Proceeds from \ne segment. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 777 $ 645 $ (4,142) $ (8,978) 1 389 322 (2,117) (4,896) (1) (389) (305) 2,169 5,927 (2) (777) (610) 4,350 13,169 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 777 $ 645 $ (4,142) $ (8,978) 1 389 322 (2,117) (4,896) (1) (389) (305) 2,169 5,927 (2) (777) (610) 4,350 13,169 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. Top negative sentences: By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Forward-looking snippets: Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. We will continue seeking to balance growth and profitability across all these dimensions. We expect broad-based competition to continue as the industry adapts to individual and employer needs. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships."
}